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doi:10.1016/j.ejvs.2010.08.007Abstract Objectives: Comparison of sapheno-femoral ligation and stripping (SFL/S) versus
endovenous laser ablation (EVLA, 980-nm) in the treatment of great saphenous vein (GSV)
insufficiency, using local tumescent anaesthesia.
Design: Randomised, single centre trial.
Materials and methods: Patients with GSV incompetence and varicose veins were randomised
to either SFL/S or EVLA. At days 1, 2, 3, 7, 10, and 14 post-treatment, patients completed
questionnaires on pain and quality of life. Recurrent varicose veins were evaluated by Duplex
ultrasound (DUS) performed at 1 and 6 weeks, and 6 and 12 months.
Results: 130 legs in 121 patients were treated by SFL/S (nZ 68) or EVLA (nZ 62). Significantly
more post-treatment pain was noted after EVLA at days 7, 10 and 14 (p< 0.01; p< 0.01;
pZ 0.01), more hindrance in mobility at days 7 (p< 0.01) and 10 (pZ 0.01), and in self care
(pZ 0.03) and daily activities (pZ 0.01) at day 7 compared to SFL/S. DUS at 1-year follow-up
showed 9% recurrences (5/56) after EVLA and 10% (5/49) after SFL/S.
Conclusion: Both SFL/S and EVLA, using local tumescent anaesthesia, were well tolerated,
with no difference in short-term recurrence rate. In the second week after EVLA, patients
experienced significantly more pain resulting in restricted mobility, self care and daily activity
compared to SFL/S.
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Varicose veins is a common health problem in Western
countries, with a prevalence between 10 and 50%.1e3
Several risk factors for the development of varicose veins
have been described, such as age, sex, positive family
history, and pregnancy.4e6 Varicose veins may be asymp-
tomatic but many patients have symptoms such as pain,
heaviness, ankle oedema, skin changes, or venous leg
ulcers. The most frequent cause of varicose veins is
incompetence of the sapheno-femoral junction (SFJ) and
the great saphenous vein (GSV).
The surgical method of sapheno-femoral ligation and
stripping (SFL/S) is considered the gold standard in the
treatment of the insufficient GSV. However, during the last
decade several minimal invasive techniques have been
developed to treat the incompetent GSV, such as endove-
nous laser ablation (EVLA) and radiofrequency ablation
(RFA). These new techniques have become an increasingly
popular alternative to surgical treatment.
Several studies of endovenous treatments for varicose
veins have demonstrated less postoperative complications
and a better quality of life (QoL) score compared conven-
tional surgery by SFL/S, and a high occlusion rate.7e10
However, up to now only one randomised trial has been
published that compared short-term post-treatment
outcome after SFL/S and EVLA in the treatment of the
incompetent GSV under tumescent anaesthesia.11
The aim of this study was to compare post-treatment
QoL and pain score, complications, and post-treatment GSV
recurrence rate after SFL/S and EVLA performed under
local tumescent anaesthesia, for a total follow-up period of
10 years. This article presents our findings covering one
year post-treatment follow-up, focussing on QoL and pain.
Materials and methods
This study was designed as a prospective, non blinded, rand-
omised, active controlled trial in an outpatient clinic spe-
cialising in venous disease (more than 1200 surgical
procedures per year, performed under local tumescent
anaesthesia only). The study protocol was approved by the
regional ethics committee. Themain outcomemeasure of this
trial was recurrent varicose veins seen in a follow-up period of
10 years. Secondary outcome measures included QoL, post-
operative pain and complications. This article describes the
one year results, focussing on QoL and post-procedural pain.
Patients
All patients included were referred for treatment of primary
varicose veins by their general practitioner. At their first visit
patients were seen by an experienced phlebologist, who
recorded the medical history and performed a physical
examination and lower limb duplex ultrasound (DUS) (Bio-
sound Esaote MyLab 25). DUS of the lower limbs was per-
formed in an upright position, using manual compression of
the calf and the Valsalva manoeuvre to visualise flow and
reflux. Incompetence of the GSV was defined as reflux> 0.5 s
in duration following either calf compression and release or
a Valsalva manoeuvre. Patients eligible for surgery, whoagreed tohave local tumescent anaesthesia, andmetwith the
inclusion criteria, were invited to participate in the study.
Inclusion criteria included age > 18 years at randomisation,
CEAP (clinical class, etiology, anatomy, pathophysiology)
classification C2,12 GSV and sapheno-femoral junction (SFJ)
incompetence defined as reflux > 0.5 s seen on DUS imaging
with an intrafascial length of at least 15 cm measured from
the SFJ downwards, and GSV diameter between 0.3 and
1.5 cm. Exclusion criteria included previous surgical treat-
ment of the GSV, intrafascial GSV reflux length 15 cm
measured from the SFJ downwards, GSV diameter 0.3 or
 1.5 cm, pregnancy, immobility, intolerance of lidocaine,
active superficial phlebitis, previous or active deep venous
thrombosis, deepvenous insufficiency. Afterwritten informed
consent was obtained and patients agreed to inclusion in
a post-treatment follow-up study, computer randomisation
(1:1) was performed per patient for either SFL/S or EVLA. All
data collected were to be evaluated in accordance with the
Declaration of Helsinki. Patients with bilateral GSV incompe-
tence were randomised only once.Methods
During the patients’ initial visit, information on medical
history was collected, followed by physical examination,
DUS, and documentation of the CEAP classification. After
randomisation, the presence and severity of complaints
caused by chronic venous disease were recorded by using
the questionnaires. At their second visit, patients under-
went treatment and were then given questionnaires. Pain
score was measured using a visual analogue scale ranging
from 0 (no pain) to 10 (most severe pain).13,14 Quality of life
was measured using the EuroQol-5D questionnaire that is
assigned to 5 dimensions: mobility, self care, daily activi-
ties, pain and discomfort, and anxiety.15 The response to
each question was rated on a scale from 1 to 3, in which 1
represented no difference and 3 represented severe wors-
ening in comparison with the pre-treatment situation.
Treatment failure and post-treatment complications were
documented. Complications included prolonged bleeding,
wound infection, skin burns, paraesthesia, thrombus at SFJ,
and deep vein thrombosis.16,17
Follow-up visits were scheduled 1 and 6 weeks, and 6
and 12 months post-treatment. During all follow-up visits,
physical examination and DUS were performed to assess
recurrence of varicose veins. CEAP classification was
documented at one year follow-up. After both treatments,
clinical recurrence of varicose veins was defined as visible
or palpable varicosities in the area of the treated GSV,
classified as CEAP C2. DUS was performed with the
patient in the upright position, using manual compression
of the calf and the Valsalva manoeuvre to detect flow and
reflux. After SFL/S, a recurrent varicose vein on DUS was
defined as a tortuous vein in the GSV area with
a diameter 3 mm, originating in the groin and connected
with the femoral vein, and showing reflux> 0.5 s. A new
refluxing vein< 3 mm and clinically visible was also
considered as a recurrence.18,19 After EVLA, a recurrent
varicose vein on DUS was defined as the ability to compress
the GSV, or as reflux > 0.5 s in a vein originating in the groin
and connected with the femoral vein.20
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Treatments were performed by surgeons experienced in
both procedures (>250 procedures/year). Treatment
procedures were scheduled to last between 45 and 60 min.
DUS was performed in an upright position and the GSV was
marked. The diameter of the GSV was documented. A single
daily prophylactic dose of low-molecular weight heparin for
1 week was only given to high-risk patients, such as patients
with inherited coagulation disorders and patients with
a medical history of deep vein thrombosis.
Sapheno-femoral ligation and stripping
Perivenous tumescent anaesthesia (lidocaine 0.1% with
1:1 000 000 adrenalin) was administered by infiltrating
300e400 ml along the length of the GSV (Nouvag Dispenser
DP20) starting at the groin. After a groin incision, high
ligation of the GSV (0.5 cm distal of the sapheno-femoral
junction) and ligation of all tributaries were performed,
followed by insertion of a Pin stripper. Access to the GSV
was achieved through a small incision just below or above
the knee. Inversion stripping was followed by closure of the
groin and the distal wound.
Endovenous laser ablation
After the patient was positioned on the operating table
DUS-guided percutaneous access to the GSV was obtained
and followed by positioning of the laser fibre tip 2 cm below
the SFJ. Perivenous tumescent anaesthesia (lidocaine 0.1%
with 1:1 000 000 adrenalin; 300e400 ml) was administered
under ultrasonographic guidance (Nouvag Dispenser DP20).
Manual compression was applied over the GSV while
the 980-nm diode laser (Biolitec) gave 12 W continuous
laser energy. The proximal 10 cm of the incompetent GSV
was treated with an energy dose of 100 J/cm, followed by
a targeted energy dose that was determined by the dia-
meter of the GSV (0.3e0.4 cmZ 50 J/cm, 0.4e0.5 cmZ
60 J/cm, 0.5e0.6 cmZ 70 J/cm, >0.6 cmZ 80 J/cm).
Peroperative data such as diameter of GSV, length of the
treated GSV, and total amount of energy delivered was
recorded. Directly after SFL/S and EVLA treatment, scle-
rotherapy (Aethoxysclerol 0.5e3.0%, Kreussler) of residual
superficial varicose veins was performed by a phlebologist.
Short-stretch bandages (Panelast, LohmaneRauscher)
were applied on the whole leg for one week. In the second
week patients were advised to apply a foam bandage
(Rosidal, LohmaneRauscher) during daytime. Patients
were asked to complete post-treatment questionnaires
focussing on QoL, pain and patient satisfaction. For the
management of post-treatment pain, patients were advised
to take non-steroid anti-inflammatory drugs (NSAID) after
EVLA, or paracetamol after SFL/S. The SFL/S group was
advised to avoid long and heavy exercise the first day after
treatment.
Sample size and statistical methods
Sample size calculations were based on detecting a 10
percent difference in recurrent varicose veins on duplex
imaging between the treatment groups. a (type I error)
Z 0.05 and b (type II error)Z 0.20, 137 patients were
required in each group.Analyses were performed using SPSS. Nominal variables
were tested by the c2 test. For group comparisons of the
ordinal variables the ManneWhitney U test or the Krus-
kalleWallis test was used. Continuous variables were
compared using the T-test or ANOVA. For comparison of two
ordinal variables the test of Wilcoxon was used. A p< 0.05
was considered significant. The study design included per-
forming a yearly interim analysis. The one year interim
analysis focussed on post-treatment pain and QoL after
SFL/S and EVLA. Considering the measured VAS results of
pain seen at day 7 (SD1Z 1.9, n1Z 68 and SD2Z 2.7,
n2Z 62, and deltaZ 2) a power of >99% was calculated.
Results
Between June 2007 and December 2008 312 patients (333
legs) were invited to participate in the study. One hundred
and thirty legs in 122 patients with GSV insufficiency were
randomised to SFL/S (nZ 68) or EVLA (nZ 62). Two patients
were lost to follow-up after 6weeks (Fig. 1). The groupswere
homogenous for demographic characteristics, summarised
in Table 1, also showing CEAP classification at initial visit,
EVLA energy applied, and complaints of chronic venous
disease at randomisation. No difference between the two
treatments was found in pain experience during the admin-
istration of local tumescent anaesthesia. During treatment,
patients in the SFL/S group experienced significantly more
pain (VAS mean of 3.39 (SD 2.57)) compared to the EVLA
group (VAS mean 2.21 (SD 2.40; pZ 0.02)). All patients were
mobilised immediately and were discharged after 1e2 h.
During the first post-treatment day, patients treated with
SFL/S experienced significantly more hindrance in daily
activities (pZ 0.01). However, the pain score at day 7
(p< 0.01), day 10 (p< 0.01) and day 14 (pZ 0.01) was
significantly higher after EVLA (Table 2). Also, patients
treated with EVLA were significantly less mobile at day 7
(p< 0.01) and day 10 (pZ 0.01), and they experienced
significantly more hindrance in their daily activity (pZ 0.01)
and in self care at day 7 (pZ 0.03).
In both treatment groups, patients resumed daily
activities after 3 days (SFL/S mean 3.2, SD 4.0; EVLA mean
3.2, SD 4.3), returned to work after 4 days (SFL/S mean 4.2,
SD 3.7; EVLA mean 4.4, SD 5.4), and restarted sporting
activities after 10 days (SFL/S mean 10.6, SD 7.0; EVLA
mean 10.5, SD 7.1) (Table 2).
Overall, patient satisfaction was good. 79% (53/67) of the
patients in the SFL/S group and 77% (47/61) patients in the
EVLA group replied that they were willing to undergo the
same treatment again. 88% (59/67) and 84% (51/61) in the
SFL/S and EVLA group respectively, would recommend the
treatment to a friend or relative. All treatments were per-
formed successfully. No major complication such as wound
infection and deep vein thrombosis was encountered. Post-
operative bleeding was recorded in only two patients (3%)
after SFL/S, and this was effectively treated with a pressure
bandage. A thrombus at the SFJwas seen on DUS in 3 patients
(5%) oneweek after EVLA. In all cases the thrombus dissolved
without treatment and could not be detected on DUS at 6
weeks follow-up. Self-limiting paraesthesia was seen in one
patient (1%) after SFL/S and in two patients (3%) after EVLA.
One year after SFL/S a persistent neurosensory deficit,
Table 1 Patient characteristics of study population, complaints and CEAP classification.
Variable SFL/S* EVLA* c2 test
n Z 68 n Z 62 p-value
Male/female (n) 15/53 16/46 0.62
Left/Right leg (n) 27/41 27/35 0.66
Age, mean (SD) 50 (10.5) 49 (11.0) 0.68a
BMI*, mean (SD) 24.5 (3.7) 25 (3.3) 0.57a
Diameter of SFJ*, cm mean (SD) 0.92 (0.27) 0.88 (0.22) 0.43a
Diameter GSV* at knee level, cm mean (SD) 0.64 (0.14) 0.64 (0.16) 0.90a
Length of treated GSV, cm mean (SD) 40.8 (7.45)
Total joules, mean (SD) 2605 (428.4)
Joules/cm, mean (SD) 64.5 (6.8)
Pre-operative complaints
Tired legs, n (%) 35 (52) 31 (50) 0.87
Oedema, n (%) 32 (47) 21 (34) 0.13
Itching, n (%) 26 (38) 20 (32) 0.48
Cosmetic n (%) 13 (19) 13 (20) 0.79
Pain, n (%) 13 (19) 9 (15) 0.49
Restless legs n (%) 6 (9) 11 (18) 0.13
Calf cramps, n (%) 8 (12) 8 (13) 0.84
Other, n (%) 7 (10) 9 (15) 0.46
Course of complaints before operation (range) 7.0 (0.5/50) 6.5 (0/40) 0.73a
CEAP classification
C2, n (%) 26 (38) 29 (47) 0.29
C3, n (%) 36 (53) 29 (47) 0.43
C4, n (%) 5 (7) 4 (6) 0.86
C5, n (%) 1 (1) 0 (0) 0.34
SFL/S* sapheno-femoral ligation and stripping, EVLA* endovenous laser ablation, BMI* Body Mass Index, SFJ* sapheno-femoral junction,
GSV* great saphenous vein, Other* f.e. restless legs, cosmetic, tingling.
a t-test.
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Figure 1 CONSORT diagram showing trial recruitment, randomisation and treatment allocation, in terms of legs. SFL/S: sapheno-
femoral ligation and stripping. EVLA: endovenous laser ablation. Six weeks post-treatment two patients in the SFL/S group were
lost to follow-up, but as they complete their postoperative questionnaires, these could be analyzed.
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Table 2 Peri- and postoperative pain and Quality of Life.
Peri- and postoperative pain (VAS 1e10) SFL/S
n Z 68
mean (SD)
EVLA
n Z 62
mean (SD)
T-test
MWa
p-value
During tumescent 4.85 (2.48) 4.69 (2.48) 0.72
During operation procedure 3.39 (2.57) 2.21 (2.40) 0.02
Day 1 4.00 (2.34) 3.58 (2.60) 0.38
Day 2 3.12 (2.38) 3.05 (2.48) 0.86
Day 3 2.38 (2.11) 2.76 (2.53) 0.37
Day 7 1.78 (1.94) 3.74 (2.72) <0.01
Day10 1.18 (1.49) 2.65 (2.21) <0.01
Day 14 0.77 (1.46) 1.66 (2.04) 0.01
Restart daily activities, no. of days 3.20 (4.01) 3.16 (4.34) 0.96
Restart work, no. of days 4.15 (3.72) 4.38 (5.43) 0.80
Restart sport, no. of days 10.62 (6.96) 10.52 (7.12) 0.95
Daily activities (scale 0, 1, 2) mean rank mean rank
Mobility day 7 53.7 76.0 <0.01a
Mobility day 10 58.3 71.1 0.01a
Self care day 7 60.9 68.3 0.03a
Daily activity day 1 71.4 57.1 0.01a
Daily activity day 7 57.4 72.1 0.01a
Anxiety 64.0 64.0 0.98a
SFL/S: sapheno-femoral ligation and stripping, EVLA: Endovenous laser ablation.
a MW Z ManneWhitney.
Figure 2 Quality of life: cosmetic results (VAS 1e10) before
sapheno-femoral ligation and stripping (SFL/S) and endovenous
laser ablation (EVLA), and at 6 months follow-up. Six months
after treatment, patients documented significant cosmetic
improvement (p < 0.01), without differences between SFL/S or
EVLA. Pre-operative median VAS was 5 in both groups (IQRZ 2
for SFL/S; IQRZ 4 for EVLA). After 6 months median VAS was 7
(IQR Z 2) for SFL/S, and median VAS was 7.5 (IQR Z 2) for
EVLA.
Surgery versus Endovenous Laser Ablation 653caused by saphenous nerve injury, was found in one patient
(1%). Six months after treatment, patients documented
a significant cosmetic improvement (p< 0.01), without
differences between SFL/S or EVLA (Fig. 2). After one year,
both groups showed a significant improvement in symptoms
of chronic venous disease (p< 0.01) (Table 3) and in CEAP
classification (p< 0.01). No difference in symptoms and
CEAP classification between treatment groups was noted
before operation (pZ 0.28) and after one year follow-up
(pZ 0.87) (Table 4).
One year post-treatment, no significant difference in the
development of recurrent varicose veins was seen after
SFL/S or EVLA. Five of 56 patients (9%) treated with SFL/S
showed reflux in a vein, originating in the groin and con-
nected with the femoral vein, of which three (5.4%) were
clinically visible. After EVLA, reflux was recorded in five of
49 patients (10%), of which three (6%) were clinically
visible. In two patients complete recanalization of the GSV
was seen, and in another patient partial recanalization was
detected, starting 11 cm distal to the groin.
Discussion
In recent years minimally invasive endovenous treatments
of the incompetent GSV have become increasingly popular
alternatives to conventional open varicose vein surgery
(SFL/S), not only among surgeons but also among patients.
Patients favour avoidance of SFL/S under general anaes-
thesia, assuming that this would cause more postoperative
discomfort and slower recovery compared with the endo-
venous techniques. Recruitment for the present study was
more difficult than expected because of patients’ prefer-
ence for endovenous procedures.
Table 3 Pre-operative complaints and complaints after one year.
Pre-operative c2-test One year c2-test pre/one year
SFL/S
n Z 68
EVLA
n Z 62
p-value
n Z 130
SFL/S
n Z 62
EVLA
n Z 56
p-value
n Z 118
p-value
Tired legs, n (%) 35 (52) 31 (50) 0.87 8 (13) 5 (9) 0.49 <0.01
Oedema, n (%) 32 (47) 21 (34) 0.13 10 (16) 6 (11) 0.39 <0.01
Itching, n (%) 26 (38) 20 (32) 0.48 6 (10) 3 (5) 0.50a 0.01a
Cosmetic, n (%) 13 (19) 13 (20) 0.79 8 (13) 4 (7) 0.31 <0.01
Pain, n (%) 13 (19) 9 (15) 0.49 6 (10) 1 (2) 0.12a 0.02a
Restless legs, n (%) 6 (9) 11(18) 0.13 4 (6) 7 (13) 0.43 <0.01
Calf cramps, n (%) 8 (12) 8 (13) 0.84 2 (3) 5 (9) 0.25a 0.01a
Other, n (%) 7 (10) 9 (15) 0.46 1 (2) 2 (4) 0.60a 0.52a
SFL/S: Sapheno-femoral ligation and stripping, EVLA: Endovenous laser ablation.
a 1 or 2 cells have expected count less than 5 so Fisher Exact test (2-sided) is performed.
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conventional surgery by SFL/S, when performed under local
tumescent anaesthesia, was well tolerated and the amount
of post-treatment complications after both treatments was
equally low.
The suggestion of more post-treatment pain in the EVLA
group was confirmed by the one year interim analysis. The
significantly higher rate of post-treatment pain after 980-nm
laser treatment was considered of such clinical relevance,
that we decided to stop further inclusion of patients in this
trial. Our observation of elevated pain andmore hindrance in
daily activities in the second week after EVLA is in contrast
with results reported in other publications. To our knowl-
edge, a comparison of SFL/S with EVLA, using a laser with
similar wavelength and both treatments performed under
local tumescent anaesthesia, has been described in only one
other randomised study, i.e. by Rasmussen et al.11 In their
study, significantly more pain and bruising 12 days post-
operative was noted after SFL/S in comparison with EVLA,
but time to resume normal activity (SFL/S mean 7.7; EVLA
mean 6.9 days) and work was equal after both treatments
(SFL/S mean 7.6; EVLA mean 7.0 days).
Darwood et al. compared two forms of EVLA performed
under tumescent anaesthesia (810-nm; continuous and
stepwise laser withdrawal) with SFL/S performed under
general anaesthesia. They found no difference in post-
operative pain after SFL/S or EVLA, but return to normal
activity, as well as return to work, was significantly faster
after both forms of EVLA than after SFL/S.21 Kalteis et al.Table 4 CEAP classification before and one year postoperative
CEAP preoperative c2-test
SFL/S EVLA total p-value
68 62 130
C0, n (%) 0 0 0
C1, n (%) 0 0 0
C2, n (%) 26 (38) 29 (47) 55 (42) 0.33
C3, n (%) 36 (53) 29 (47) 65 (50) 0.48
C4, n (%) 5 (7) 4 (7) 9 (7) 0.84
C5, n (%) 1 (1.5) 0 1 (1)
SFL/S: Sapheno-femoral ligation and stripping, EVLA: Endovenous lascompared high ligation combined with either EVLA (810-
nm) or stripping, both performed under general anaes-
thesia. They found no difference in postoperative pain, but
EVLA combined with high ligation was associated with
a longer period of time needed to return to work compared
with SFL/S.22
Post-procedural pain, bruising and some restrictions in
normal daily activities after SFL/S and EVLA have been well
described10,23 These are known symptoms and are of short
duration. However, pain and bruising after EVLA are espe-
cially common after treatment with lasers that use hae-
moglobin-specific wavelengths (810 nm, 940 nm,
980 nm).8,23,24 It has been demonstrated that those endo-
vascular laser techniques can cause vein perforations.25,26
Such vein perforations lead to extravasation of blood into
the surrounding tissues, which causes bruising and pai-
n.27Although these symptoms are mostly of mild intensity
and self-limiting after one or two weeks, they may lead to
hindrance in daily activities. We therefore speculate that
these observations might well be the underlying cause of
our findings of more pain and delay in starting in daily
activities after EVLA. Due to these findings, we decided to
stop the inclusion for this trial, but we will continue the
follow up of the reported patients. We prefer the use of
other endovenous techniques such as radiofrequency
ablation (VNUS ClosureFAST) and 1470 nm laser (Biolitec).
Additionally, in our study, the post-treatment pain after
SFL/S may have been reduced by the local tumescent
anaesthesia. Compression of the GSV tunnel and the local.
CEAP one year postoperative c2-test
SFL/S EVLA total p-value
61 56 117
21 (34) 19 (31) 37 (46) 0.96
22 (36) 20 (36) 34 (33) 0.97
11 (18) 9 (16) 16 (16) 0.78
6 (10) 7 (13) 13 (13) 0.65
0 1 (2) 1 (1)
1 (2) 0 1 (1)
er ablation.
Surgery versus Endovenous Laser Ablation 655application of lidocaine and adrenalin have been found to
reduce haematoma and to diminish postoperative pain.11,28
After SFL/S, complication rates up to 30% are described,
however, in the present study postoperative complications
were recorded in only 3% of the patients.29 No deep vein
thrombosis was seen, despite the fact that no routine
perioperative anticoagulant therapy was administered. In
public literature, the recurrence rate after varicose vein
surgery has been reported to vary between 6 and 62%,
depending on the follow-up period and the definition of the
condition.19,30e32 In the present study, the prevalence of
recurrent varicose veins one year after SFL/S was 9%.
In a prospective, non-randomised study, Proebstle et al.
demonstrated less than 10% recanalization of the GSV up to
one year after EVLA (940 nm).10 In another prospective, non-
randomised study, Min et al. reported a recurrence rate,
defined as recanalization of theGSVonDUS, of less than 7% at
2-year follow-up after EVLA (810 nm).24 These percentages
resemble ours, as we found complete recanalization of the
GSV in 2 of 49 patients (4.1%) at one year follow-up after
EVLA, and partial recanalization of the GSV in one patient. It
has been debated whether a correlation exists between the
EVLA induced occlusion rate of the incompetent GVS and the
amount of energy administered during the procedure. In the
study of Theivacumar et al. an energy density> 60 J/cm is
recommended. In the present study EVLA was performed
with an average energy density of 64.5 SD 6.8 J/cm.
This study had some limitations. Due to practical diffi-
culties in scheduling follow-up visits in our clinic, it was not
possible to invite consecutive patients for recruitment in this
study. Neither the patients, nor the doctors could be blinded
for the treatment. Therefore, patients’ expectations might
have influenced the outcome measures regarding post-
treatment pain and QoL. Because of practical drawbacks,
the assessment of recurrent varicose veins during the follow-
up visits was not performed by an independent observer.
In conclusion, both conventional surgery by SFL/S and
endovenous laser ablation (EVLA), performed under local
tumescent anaesthesia, were well tolerated, with no
differences in complications, short-term cosmetic results,
CEAP classification, and recurrence rate. However, in the
second week of post-treatment QoL assessment, patients in
the EVLA group experienced significantly more pain
resulting in a restriction of mobility, self care and daily
activities than noted after SFL/S.
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